drugset / Trial / NCT00670033

Travoprost New Formulations in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT00670033

Phase 2 Completed 158 enrolled Alcon Research
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study was to describe the safety and IOP-lowering efficacy of Travoprost New Formulations compared to TRAVATAN® and to vehicle in patients with open-angle glaucoma or ocular hypertension.

Timeline

Start
2008-04
Primary completion
2008-09
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Travoprost Other / unclassified 0.004 % Other
Comparator Travoprost Other / unclassified Other